{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:18:19Z","timestamp":1759335499173},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.antiviral.2014.06.018","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T17:16:39Z","timestamp":1405617399000},"page":"77-78","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Hepatitis C: The next 25 years"],"prefix":"10.1016","volume":"110","author":[{"given":"Michael","family":"Houghton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4902","key":"10.1016\/j.antiviral.2014.06.018_b0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"4902","key":"10.1016\/j.antiviral.2014.06.018_b0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1126\/science.2496467","article-title":"An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis","volume":"244","author":"Kuo","year":"1989","journal-title":"Science"},{"issue":"115","key":"10.1016\/j.antiviral.2014.06.018_b0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2014.06.018_b0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/liv.12424","article-title":"Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir","volume":"34","author":"Asselah","year":"2014","journal-title":"Liver Int."},{"issue":"7294","key":"10.1016\/j.antiviral.2014.06.018_b0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"issue":"5424","key":"10.1016\/j.antiviral.2014.06.018_b0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"issue":"5498","key":"10.1016\/j.antiviral.2014.06.018_b0035","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.antiviral.2014.06.018_b0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/liv.12304","article-title":"Impact of coffee on liver diseases: a systematic review","volume":"34","author":"Saab","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2014.06.018_b0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2014.01.002","article-title":"Can hepatitis C virus infection be eradicated in people who inject drugs?","volume":"104","author":"Grebely","year":"2014","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.antiviral.2014.06.018_b0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.antiviral.2014.06.018_b0055","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1128\/JVI.75.15.7142-7148.2001","article-title":"Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity","volume":"75","author":"Weiner","year":"2001","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2014.06.018_b0060","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/JVI.78.3.1575-1581.2004","article-title":"Cross-genotype immunity to hepatitis C virus","volume":"78","author":"Lanford","year":"2004","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.antiviral.2014.06.018_b0065","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection","volume":"197","author":"Shoukry","year":"2003","journal-title":"J. Exp. Med."},{"issue":"5645","key":"10.1016\/j.antiviral.2014.06.018_b0070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"Walker CM.HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.06.018_b0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.02.013","article-title":"The past, present and future of neutralizing antibodies for hepatitis C virus","volume":"105","author":"Ball","year":"2014","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.antiviral.2014.06.018_b0080","doi-asserted-by":"crossref","first-page":"e59776","DOI":"10.1371\/journal.pone.0059776","article-title":"A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans","volume":"8","author":"Law","year":"2013","journal-title":"PLoS One"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T11:53:23Z","timestamp":1572436403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":16,"alternative-id":["S0166354214001806"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.06.018","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C: The next 25years","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}